TNF and rheumatoid arthritis: For example, the first registry (ARBITR) was launched in Russia in 2005 when the first agent for biological therapy, an anti-TNFα drug (infliximab) was registered.14 Starting in 2011, it was transformed into the OREL registry, which quickly developed as an internet-based project and now includes 3,276 RA patients.17